期刊文献+

慢性空洞性肺曲菌病临床表现 被引量:2

Clinical manifestation of chronic cavitary pulmonary aspergillosis
原文传递
导出
摘要 目的探讨慢性空洞性肺曲菌病的临床症状、影像学特点、诊断和治疗方法。方法对3例误诊为肺结核而长期抗结核治疗无效,甚至导致肺毁损,经手术切除病变肺叶或经支气管肺活检术,病理确诊为慢性空洞性肺曲菌病的临床资料进行总结。结果慢性空洞性肺曲菌病常见的临床症状为慢性咳嗽、疲劳不适,严重者出现气短。影像学显示空洞出现在肺上叶,且进行性增大,有时为多发。组织学检查在空洞内可找到真菌菌丝,周围肺组织有慢性炎症和肺纤维化,伴有胸膜肥厚。结论慢性空洞性肺曲菌病是慢性肺曲菌病的一种亚型,临床上少见,常见影像学特点是肺内空洞进行性增大,组织学检查在空洞内可找到真菌菌丝,治疗上需积极抗真菌,必要时可手术。 Objective To discuss the clinical manifestation, imaging characteristic, diagnosis and treatment of chronic cavitary pulmonary aspergillosis (CCPA). Methods Clinical data of three patients with CCPA were summarized,who had ever been misdiagnosed as pulmonary tuberculosis for a long time and failed to treatment with antituberculosis drugs, even aggravated to have lung injury, and were pathologically confirmed as CCPA by surgery or transbronchial lung biopsy. Results Chronic cough, fatigue,or short breath were common clinical symptoms of CCPA. Imaging results showed that cavitary lesions appeared in the upper lobe of lung,which increased progressively,and sometimes were multiple. Histological examination showed that fungal hyphae cound be found in the cavity, chronic inflammation and pulmonary fibrosis appeared in surrounding lung tissue, accompanying pleural thickening. Conclusions CCPA is a subtype of chronic pulmonary aspergillosis, which is rare in clinic. The imaging characteristic is mainly that cavitary lesions increase progressively. Fungal hyphae can be found in the cavity by histological examination. For CCPA patients,antifungal therapy should be taken actively, and surgery can be taken if necessary.
出处 《国际呼吸杂志》 2010年第8期472-476,F0003,共6页 International Journal of Respiration
关键词 慢性 空洞 曲霉菌 Chronic Cavity Pulmonary Aspergillus
  • 相关文献

参考文献15

  • 1Park CK,Jheon S.Results of surgical treatment for pulmonary aspergilloma.Eur J Cardiothorac Surg,2002,21:918-923.
  • 2朱小敏,周新.侵袭性肺曲霉病的诊断与治疗[J].中国呼吸与危重监护杂志,2005,4(4):316-320. 被引量:36
  • 3Denning DW,Riniotis K,Dobrashian R,et al.Chronic cavitary and fibrosing pulmonary and pleural aspergillosis:case series,proposed nomenclature change,and review.Clin Infect Dis,2003,37:S265-S280.
  • 4Crosdale DJ,Pouhon KV,Ollier WE,et al.Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis.J Infect Dis,2001,184:653-656.
  • 5Madan T,Kishore U,Singh M,et al.Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis.Infect Immun,2001,69:2728-2731.
  • 6Madan T,Kishore U,Singh M,et al.Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens.J Clin Invest,2001,107:467-475.
  • 7Neth O,Jack DL,Dodds AW,et al.Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition.Infect Immun,2000,68:688-693.
  • 8Saraceno JL,Phelps DT,Ferro TJ,et al.Chronic necrotizing pulmonary aspergillosis:approach to management.Chest,1997,112:541-548.
  • 9Rogers PD,Stiles JK,Chapman SW,et al.Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1.J Infect Dis,2000,182:1280-1283.
  • 10Kim JH,Ahn YK.The effects of itraconazole on the immune responses in ICR mice.J Toxicol Sci,1994,19:7-15.

二级参考文献27

  • 1Becker M J, Lugtenburg E J, Cornelissen J J, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol, 2003; 121:448 ~ 457
  • 2Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphoteric in B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis, 2000;31:1155~ 1163
  • 3Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative studies on the efficacy of AmBisome and fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother,2004;53:311 ~ 317
  • 4Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol, 2003; 109: 111 ~ 118
  • 5Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med ,2002;347:408 ~ 415
  • 6Yuet W. Voriconazole versue amphotericin for primary therapy of invasive aspergillosis. N Engl J Med, 2002; 347: 408 ~ 415
  • 7Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother, 2001 ;45: 857 ~ 869
  • 8Taccone FS, Marechal R, Meuleman N, et al. Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Care Cancer, 2003; 11: 742 ~744
  • 9Lewis RE, Prince RA, Chi J, et al. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother,2002;46:3208~ 3214
  • 10Popp AI, White MH, Quadri T, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis, 1999 ;3:157~ 160

共引文献35

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部